CYP3A4 and angina pectoris: However, when patients receiving Diltiazem/Verapamil or strong CYP3A4 inhibitors are excluded from analysis, the difference between groups (with or without severe angina) and the harmful effect of Ivabradine among patients with severe angina disappear (Fig. 7).